Peripheral neuropathic pain is among the most stubborn and debilitating conditions in modern medicine, a burning, shooting, or electric-shock-like torment that arises when nerves themselves are damaged by diabetes, chemotherapy, trauma, or infection. For millions of patients, relief has long meant swallowing pills that bathe the entire body in medication on their slow road to the brain. Now, a team of pharmaceutical scientists in India has reimagined one of the most widely prescribed nerve-pain drugs as something patients could simply rub onto their skin. In a study published in Applied Nanoscience, researchers at Jamia Hamdard in New Delhi report the successful design and testing of a topical gel built around nanostructured lipid carriers — submicroscopic fat-based particles engineered to ferry gabapentin, a drug notoriously difficult to deliver through the skin, directly into the nerves beneath the site of pain.
Gabapentin occupies a curious place in the pharmacopeia. Originally developed as an analog of the neurotransmitter GABA, it does not actually act on GABA receptors at all. Instead, it binds to the α2δ-1 subunit of voltage-gated calcium channels, damping the excessive calcium influx into overexcited neurons that underlies neuropathic pain signaling. It remains a first-line therapy for conditions such as diabetic neuropathy, postherpetic neuralgia, and sciatica. Yet the drug carries well-known liabilities when taken orally: dizziness, somnolence, and fatigue are common, and its absorption from the gut is saturable and variable, meaning that higher doses do not translate proportionally into higher blood levels. Those limitations have long tempted formulation scientists to attempt a topical version — but gabapentin is a small, highly water-soluble, hydrophilic molecule, precisely the kind of compound that struggles to breach the skin’s lipid-rich outer barrier, the stratum corneum.
The Jamia Hamdard team, led by Parnika Vasudeva and Shama Parveen, who contributed equally as first authors, alongside colleagues including Ahsan Ali, Vijay Kumar, Pooja Jain, Mohd. Aamir Mirza, and senior author Zeenat Iqbal, attacked this permeability problem with nanostructured lipid carriers, or NLCs. These particles represent a second-generation evolution of solid lipid nanoparticles. Where their predecessors were built from a single solid lipid prone to crystallizing into an orderly lattice that expelled trapped drug molecules over time, NLCs blend a solid lipid with a liquid lipid in deliberate imbalance. The resulting imperfect, porous matrix has room for drug molecules to hide, boosting how much drug each particle can carry and preventing the payload from leaking out during storage.
To build their carriers, the researchers turned to a systematic engineering philosophy known as quality by design, or QbD — an approach borrowed from manufacturing science in which formulation variables are treated as inputs to be rationally optimized rather than trial-and-error guesses. The team varied critical parameters and measured four key quality attributes of the resulting nanoparticles: particle size, zeta potential, drug entrapment efficiency, and in vitro drug release. Each of these numbers matters. Particle size governs how densely the carriers can pack onto the skin surface and how readily they slip into hair follicles and microscopic skin furrows. Zeta potential — the electrical charge at the particle surface — predicts whether particles will repel one another and remain stably dispersed or clump into useless aggregates. Entrapment efficiency reveals what fraction of the expensive drug payload actually ended up inside the carriers rather than floating free in the watery surroundings.
The optimization paid off. The winning formulation produced particles averaging just 144.4 nanometers in diameter — small enough that roughly 700 particles lined up side by side would span the width of a human hair. The system was moderately polydisperse, with a polydispersity index of 0.331, indicating a reasonably uniform population of carriers. The zeta potential measured −27.2 millivolts, a strongly negative surface charge comfortably within the range generally considered sufficient to keep nanoparticles from aggregating through electrostatic repulsion. Perhaps most importantly, the carriers succeeded at the very task that makes topical gabapentin so difficult: by tucking the hydrophilic drug inside a lipid shell, they created a vehicle in which gabapentin can partition into, and diffuse across, the lipophilic stratum corneum far more effectively than the free drug ever could.
With the nanoparticles optimized, the next step was to convert them into something a patient could actually use. The researchers dispersed their NLC formulation into a gel matrix built from Carbopol 934, a synthetic polymer that swells in water to form a smooth, translucent, and highly stable gel. The finished 1 percent NLC gel was assessed against the practical criteria that determine whether a topical product will ever leave the laboratory: homogeneity, spreadability, pH, and extrudability — that is, how easily the gel can be squeezed from a tube. The formulation scored well across the board, exhibiting excellent homogeneity and spreadability, a skin-friendly pH, and smooth extrusion, all essential properties for a product intended for daily self-application on painful limbs.
The drug release behavior of the gel proved equally encouraging. In laboratory dissolution testing, 96.88 percent of the loaded gabapentin was released from the optimized NLC gel over six hours. When the researchers plotted the release data against mathematical kinetic models, the profile followed the Higuchi model — the classic signature of diffusion-controlled release from a matrix. In practical terms, this means the drug does not burst out all at once but instead diffuses steadily out of the lipid matrix at a rate governed by the square root of time, exactly the sustained, gradual delivery profile desired for a pain therapy that must keep working between applications.
The true test, however, had to come from living nerves. The team turned to a widely used animal model of neuropathic pain known as chronic constriction injury, or CCI. In this model, Wistar rats undergo surgical loosening of the sciatic nerve, producing partial denervation that mirrors the mechanical nerve damage seen in human conditions such as sciatica and complex regional pain syndrome. Within days, the injured nerve generates the hallmark abnormalities of neuropathic pain: heightened sensitivity to heat and touch, known as hyperalgesia, and pain responses to normally innocuous stimuli, known as allodynia.
Rats with CCI-induced nerve injury were treated with the gabapentin-loaded NLC gel, and their pain responses were evaluated using two established behavioral assays of thermal sensitivity: the tail-immersion test, which measures how quickly an animal withdraws its tail from warm water, and the hot plate test, which measures latency to respond when placed on a heated surface. The treated animals showed promising improvements in heat sensitivity across both tests, indicating that the drug delivered through the skin was reaching functional targets and dampening the aberrant nerve signaling produced by the injury. The result demonstrates that enough gabapentin penetrated the rat skin to exert a pharmacodynamic effect at the peripheral nerves — the central hurdle that has defeated simpler topical gabapentin attempts in the past.
The implications extend beyond one drug and one disease. Peripheral neuropathic pain affects a substantial fraction of people with diabetes, and it complicates cancer chemotherapy, shingles infection, spinal surgery, and traumatic nerve injury. Current consensus guidelines place gabapentin and its cousin pregabalin at the top of the pharmacological ladder, but their systemic side effects force many patients to abandon treatment. A topical alternative that concentrates drug delivery at the painful site while minimizing blood levels could transform daily management, offering relief with a fraction of the dizziness and drowsiness that undermine oral therapy. The lipid nanoparticles themselves may also provide synergistic benefits: lipid-based carriers are known to interact with and disrupt the stratum corneum’s lipid architecture transiently, opening transient channels for penetration, and their occlusive film-forming behavior on the skin can further enhance hydration and permeability.
The authors conclude that a gabapentin-containing NLC gel can be a better alternative to oral formulations and merits further exploration for peripheral neuropathic pain. There is still a considerable distance between a rat model and a pharmacy shelf. The findings will need confirmation in larger animal studies, formal skin toxicity and irritation testing, pharmacokinetic measurements of how much drug reaches the bloodstream versus the target tissue, and ultimately carefully controlled clinical trials in human patients. Dose optimization, long-term stability of the gel, and scalability of the manufacturing process will all demand attention. But the study offers a compelling proof of concept: that quality-by-design engineering of nanostructured lipid carriers can coax a stubbornly hydrophilic drug through the body’s most formidable barrier and quiet damaged nerves where they misfire. For the millions who live with burning feet and shooting limb pain, the prospect of relief from a simple tube of gel — without the fog of systemic side effects — is a future worth watching closely.
Subject of Research: Formulation, optimization, and evaluation of a topical nanostructured lipid carrier (NLC) gel encapsulating gabapentin for the management of peripheral neuropathic pain
Subject of Research: Technology and Engineering
Article Title: Formulation of topical nano lipidic carrier gel encapsulating Gabapentin to combat peripheral neuropathic pain
Article References: Vasudeva, P., Parveen, S., Ali, A., Kumar, V., Siddiqui, A., Farooq, U., Jain, P., Mirza, M. A., & Iqbal, Z. (2026). Formulation of topical nano lipidic carrier gel encapsulating Gabapentin to combat peripheral neuropathic pain. Applied Nanoscience, 16(3), Article 37. https://doi.org/10.1007/s13204-026-03157-7
Image Credits: AI Generated
DOI: 10.1007/s13204-026-03157-7
Keywords: Gabapentin, nano lipid carrier, chronic constriction injury, peripheral neuropathic pain, gel, topical drug delivery, quality by design, Higuchi release kinetics, Carbopol 934, transdermal delivery
Cite Scienmag News
APA MLA Chicago
Denise Maddox. (September 7, 2026). Gabapentin-loaded nano lipid gel offers new topical relief for neuropathic pain. Scienmag. https://scienmag.com/gabapentin-loaded-nano-lipid-gel-offers-new-topical-relief-for-neuropathic-pain/
Denise Maddox. “Gabapentin-loaded nano lipid gel offers new topical relief for neuropathic pain.” Scienmag, 7 September 2026, https://scienmag.com/gabapentin-loaded-nano-lipid-gel-offers-new-topical-relief-for-neuropathic-pain/. Accessed 7 September 2026.
Denise Maddox. “Gabapentin-loaded nano lipid gel offers new topical relief for neuropathic pain.” Scienmag. September 7, 2026. https://scienmag.com/gabapentin-loaded-nano-lipid-gel-offers-new-topical-relief-for-neuropathic-pain/
Copy citation Download RIS
Tags: chemotherapy-induced neuropathydiabetes-related nerve paindiabetic neuropathy treatmentdrug delivery challenges in neuropathic painGabapentin-loaded nano lipid gelinnovative neuropathy therapiesinnovative pain treatment solutionslipid-based drug delivery systemslipid-based drug nanocarrierslocalized pain relief therapiesnano lipid carriers for drug deliverynanomedicine for chronic painnanostructured lipid carriersnanotechnology in pain managementnanotechnology in pharmaceuticalsneuropathic pain managementneuropathic pain treatmentpharmaceutical nanotechnologytopical gabapentin geltopical neuropathic pain relieftopical treatment for nerve paintransdermal drug delivery
